rs11558754
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_002340.6(LSS):c.363C>T(p.Ala121Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.157 in 1,613,614 control chromosomes in the GnomAD database, including 20,596 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.14 ( 1646 hom., cov: 34)
Exomes 𝑓: 0.16 ( 18950 hom. )
Consequence
LSS
NM_002340.6 synonymous
NM_002340.6 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -4.17
Genes affected
LSS (HGNC:6708): (lanosterol synthase) The protein encoded by this gene catalyzes the conversion of (S)-2,3 oxidosqualene to lanosterol. The encoded protein is a member of the terpene cyclase/mutase family and catalyzes the first step in the biosynthesis of cholesterol, steroid hormones, and vitamin D. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Feb 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
BP6
Variant 21-46222695-G-A is Benign according to our data. Variant chr21-46222695-G-A is described in ClinVar as [Benign]. Clinvar id is 677219.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-4.18 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.166 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LSS | NM_002340.6 | c.363C>T | p.Ala121Ala | synonymous_variant | 4/22 | ENST00000397728.8 | NP_002331.3 | |
LSS | NM_001001438.3 | c.363C>T | p.Ala121Ala | synonymous_variant | 4/23 | NP_001001438.1 | ||
LSS | NM_001145436.2 | c.363C>T | p.Ala121Ala | synonymous_variant | 4/22 | NP_001138908.1 | ||
LSS | NM_001145437.2 | c.123C>T | p.Ala41Ala | synonymous_variant | 3/21 | NP_001138909.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LSS | ENST00000397728.8 | c.363C>T | p.Ala121Ala | synonymous_variant | 4/22 | 1 | NM_002340.6 | ENSP00000380837.2 |
Frequencies
GnomAD3 genomes AF: 0.144 AC: 21859AN: 152176Hom.: 1644 Cov.: 34
GnomAD3 genomes
AF:
AC:
21859
AN:
152176
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.136 AC: 34011AN: 250330Hom.: 2441 AF XY: 0.137 AC XY: 18485AN XY: 135382
GnomAD3 exomes
AF:
AC:
34011
AN:
250330
Hom.:
AF XY:
AC XY:
18485
AN XY:
135382
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.158 AC: 230683AN: 1461320Hom.: 18950 Cov.: 32 AF XY: 0.157 AC XY: 113788AN XY: 726954
GnomAD4 exome
AF:
AC:
230683
AN:
1461320
Hom.:
Cov.:
32
AF XY:
AC XY:
113788
AN XY:
726954
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.144 AC: 21875AN: 152294Hom.: 1646 Cov.: 34 AF XY: 0.138 AC XY: 10270AN XY: 74454
GnomAD4 genome
AF:
AC:
21875
AN:
152294
Hom.:
Cov.:
34
AF XY:
AC XY:
10270
AN XY:
74454
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
370
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 24, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
LSS-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 15, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at